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Introduction: Surveillance of antimicrobial medicines consumption is central to
improving their use and reducing resistance rates. There are few published data on
antibiotic consumption in Eastern Europe and Central Asia. To address this, 18 non-
European Union (EU) countries and territories contribute to the WHO Regional Office for
Europe (WHO Europe) Antimicrobial Medicines Consumption (AMC) Network.
Objectives: (i) Analyze 2015 consumption of J01 class antibacterials for systemic use
from 16 AMC Network members; (ii) compare results with 2011 data and 2015 ESAC-
Net estimates; (iii) assess consumption against suggested indicators; (iv) evaluate the
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impact of planned changes to defined daily doses (DDDs) in 2019 for some commonly
used antibiotics; and (v) consider the utility of quantitative metrics of consumption for
policy action.
Methods: Analysis methods are similar to ESAC-Net for EU countries. The Anatomical
Therapeutic Chemical (ATC) classification and DDD methodology were used to
calculate total consumption (DDD/1000 inhabitants/day [DID]), relative use measures
(percentages), extent of use of WHO Watch and Reserve group antibiotics and impact
of DDD changes.
Findings: Total J01 consumption in 2015 ranged 8.0–41.5 DID (mean 21.2 DID),
generally lower than in 2011 (6.4–42.3 DID, mean 23.6 DID). Beta-lactam penicillins,
cephalosporins, and quinolones represented 16.2–56.6, 9.4–28.8, and 7.5–24.6% of
total J01 consumption, respectively. Third-generation cephalosporins comprised up to
90% of total cephalosporin consumption in some countries. Consumption of WHO
Reserve antibiotics was very low; Watch antibiotics comprised 17.3–49.5% of total
consumption (mean 30.9%). Variability was similar to 2015 ESAC-Net data (11.7–
38.3 DID; mean 22.6 DID). DDD changes in 2019 impact both total and relative
consumption estimates: total DIDs reduced on average by 12.0% (7.3–35.5 DID), mostly
due to reduced total DDDs for commonly used penicillins; impact on rankings and
relative use estimates were modest.
Discussion: Quantitative metrics of antibiotic consumption have value. Improvements
over time reflect national activities, however, changes in total volumes may conceal shifts
to less desirable choices. Relative use measures targeting antibiotics of concern may
be more informative. Some, including WHO Watch and Reserve classifications, lend
themselves to prescribing targets supported by guidelines and treatment protocols.
Keywords: antibiotic utilization, antimicrobial medicines consumption, national surveillance networks, cross-
national comparative study, Eastern Europe, Central Asia, quality indicators
INTRODUCTION
The rise in antimicrobial resistance (AMR) is a growing public
health concern impacting on morbidity, mortality and costs,
calling for urgent action as local problems with resistance
become a global threat (Gandra et al., 2014; Michael et al.,
2014; Taylor et al., 2014; O’Neill, 2015; Prestinaci et al., 2015;
Jinks et al., 2016; United Nations, 2016; Jakovljevic et al.,
2018). Strengthening the evidence base through surveillance of
AMR and antimicrobial medicines consumption, and optimizing
antimicrobial medicines use in human and animal health,
are two of the five objectives of the Global Action Plan
(GAP) to reduce AMR (World Health Organization, 2015).
To implement the GAP, the World Health Assembly in 2015
urged Member States to develop national action plans on AMR
that aligned with the objectives of the GAP (World Health
Organization, 2016). Routine data collection on antimicrobial
consumption in Europe predated the GAP, with reference data
on antimicrobial medicines consumption from European Union
(EU) member countries along with Norway and Iceland available
from 1997 (European Centre for Disease Prevention and Control
[ECDC], 2018). The European Surveillance of Antimicrobial
Consumption (ESAC) Network (ESAC-Net) utilizes standardized
methods to collect and analyze antimicrobial consumption data
for both the community and the hospital sector [European
Centre for Disease Control (ECDC), 2018]. Since 2011, similar
methods have been used in the WHO Regional Office for Europe
(WHO Europe) Antimicrobial Medicines Consumption (AMC)
Network to estimate antimicrobial medicines consumption in
18 non-EU countries and territories of the WHO European
region. As with ESAC-Net, data collection is based on the
WHO Anatomical Therapeutic Chemical (ATC) classification
system and defined daily doses (DDDs) methodology (WHO
Collaborating Centre for Drug Statistics Methodology, 2018a,b).
This work supplements local studies on patterns of antimicrobial
consumption (Stratchounski et al., 2001; Malo et al., 2014;
Smiljanic et al., 2016).
2011 data from selected countries of the WHO Europe AMC
Network were published in 2014 and an analysis of AMC data
for 2011–2014 published in 2017 (Versporten et al., 2014; World
Health Organization Regional Office for Europe, 2017a). Both
analyses reported total consumption of J01 antibacterials for
systemic use (DDD per 1000 inhabitants per day [DID]), and
the relative use of different pharmacological subgroups including
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tetracyclines, penicillins, cephalosporins, aminoglycosides,
macrolides, and quinolones. These analyses also reported the
relative consumption of agents recommended as second-line
treatment choices including cephalosporins (particularly third-
and fourth-generation agents) and quinolones on the basis that
these metrics might focus attention on areas where antibiotic
use could be improved. Despite some differences in data sources
used and differences in levels of expenditure on medicines
between Western and Eastern Europe (Jakovljevic et al., 2016),
comparisons between ESAC-Net and AMC data were presented,
giving a pan-European perspective on antibiotic consumption
(Versporten et al., 2014; World Health Organization Regional
Office for Europe, 2017a). Since then, a new classification of
antibiotics introduced by WHO and some significant changes
to DDD values that will take effect in 2019 have increased
the range of metrics that might be reported and will affect
the interpretation of some existing measures of antibiotic
consumption. In addition, a number of members of the AMC
Network have reviewed their antibiotic utilization patterns
alongside ongoing policies to improve utilization to provide
guidance for the future (Abilova et al., 2018; Bojanic et al., 2018),
building on activities among European countries (Adriaenssens
et al., 2011; Malo et al., 2014; Smith et al., 2014; Furst et al., 2015).
There have also been activities among AMC Network countries
and areas to improve the knowledge and activities of community
pharmacists regarding the treatment of infections in ambulatory
care as pharmacists are often the first point of contact for patients
(Markovic-Pekovic et al., 2017; Hoxha et al., 2018). This builds
on proposed WHO activities among pharmacists in Europe
(World Health Organization Regional Office for Europe, 2014).
In April 2017, the Expert Committee on the Selection
and Use of Essential Medicines recommended changes to the
WHO Model Lists of Essential Medicines for adults (EML) and
children (EMLc), following a comprehensive review of sections
6.2.1 (Beta-lactam medicines) and 6.2.2 (Other antibacterials)
(World Health Organization, 2017c). After reviewing up-to-date
evidence summaries on the treatment of 21 priority infectious
conditions (based on disease burden, severity of illness and
prospects for improving antibiotic use), five pediatric infectious
syndromes and several sexually transmitted infections (World
Health Organization, 2017a), the Committee identified empirical
first- and second-choice treatments for common, community-
acquired infections, focusing on treatment choices broadly
applicable in most countries (Sharland et al., 2018). The Expert
Committee also proposed a categorization of antibiotics into
Access, Watch, and Reserve groups (Boxes 1, 2), taking account
of recommendations of WHO and OIE (World Organisation
for Animal Health) for the management of antibacterials that
are critically important for both human and animal health
(World Organisation for Animal Health, 2015; World Health
Organization, 2017b). Not all medicines on the Model Lists
were assigned to the three groups, leaving a fourth “ungrouped”
category, with the classification to be revised as additional clinical
syndromes are reviewed (Sharland et al., 2018). However, this
classification could support antimicrobial stewardship efforts
and focus attention on prescribing practices that should be
further reviewed.
BOX 1 | WHO categories of antibiotics – descriptions.
Group Definition
Access group First- and second-choice antibiotics that should be widely
available in all countries. They should be affordable and quality
assured.
Watch group First- and second-choice antibiotics that only should be used for
a specific, limited number of indications due to higher resistance
potential.
Reserve group Last resort antibiotics that should be used only when other
antibiotics have failed or for infections of multi-resistant bacteria.
Following an application from the European Centre
for Disease Control (ECDC), in October 2017 the WHO
International Working Group for Drug Statistics Methodology
recommended changes to the DDDs for seven commonly
used antibiotics (mainly penicillins), and endorsed new DDDs
for oral colistin along with changes for a number of other
products (Box 3) (WHO Collaborating Centre for Drug Statistics
Methodology, 2018c). The changes were requested given
evidence that current DDD allocations for commonly used
medicines differed substantially from recommended doses and
doses used in clinical practice. The DDD changes will be fully
adopted in 2019 and will affect estimates of total antibiotic
medicines consumption, relative use of classes of antibiotics
and interpretation of national and cross-national comparisons
over time.
This study presents updated data from the WHO Europe
AMC Network using cross-national comparisons of 2015
antibiotic consumption data for 16 network members
where the Ministry of Health approved data sharing and
publication. Consumption estimates for 2011 and 2015 are
compared; the WHO “Watch” and “Reserve” classification of
antibiotics is applied, and the impact of proposed changes
to DDDs in 2019 are examined. In addition, we consider
the information value of different quantitative metrics to
policymakers, consumers, and health care professionals to
provide future guidance.
MATERIALS AND METHODS
Participating Countries and Areas
Sharing of the 2015 data was approved for 16 of 18 AMC
Network members – Albania, Armenia, Azerbaijan, Bosnia
and Herzegovina, Belarus, Georgia, Kazakhstan, Kyrgyzstan,
Republic of Moldova, Montenegro, Russian Federation, Serbia,
Tajikistan, Turkey, Uzbekistan, and Kosovo [in accordance with
Security Council resolution 1244 (1999)].
Data Collection
The methods used in the AMC Network have been described
elsewhere (Versporten et al., 2014; World Health Organization
Regional Office for Europe, 2017a). Briefly, data collection follows
a standardized protocol using an Excel template based on a
national register of antimicrobial medicines with marketing
authorization. Products are identified by ATC code facilitating
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BOX 2 | Medicines assigned to WHO access, watch, and reserve groups.
Access group
Medicine ATC code# Medicine ATC code#
Beta-lactam medicines Other antibacterials
Amoxicillin J01CA04 Amikacin J01GB06
Amoxicillin + clavulanic acid J01CR02 Azithromycin∗
Ampicillin J01CA01 Chloramphenicol J01BA01
Benzathine benzylpenicillin J01CE08 Ciprofloxacin∗
Benzylpenicillin J01CE01 Clarithromycin∗
Cefalexin J01DB01 Clindamycin J01FF01
Cefazolin J01DB04 Doxycycline J01AA02
Cefixime∗ Gentamicin J01GB03
Cefotaxime∗ Metronidazole J01XD01, P01AB01
Ceftriaxone∗ Nitrofurantoin J01XE01
Cloxacillin J01CF02 Spectinomycin J01XX04
Phenoxymethylpenicillin J01CE02 Sulfamethoxazole + trimethoprim J01EE01
Piperacillin + tazobactam∗ Vancomycin (oral and parenteral)∗
Procaine benzylpenicillin J01CE09
Watch group
Medicine ATC code
Quinolones and fluoroquinolones e.g., ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin J01MA, J01MB
Third-generation cephalosporins (with or without beta-lactamase inhibitor) e.g., cefixime, ceftriaxone, cefotaxime, ceftazidime J01DD
Macrolides e.g., azithromycin, clarithromycin, erythromycin J01FA
Glycopeptides e.g., teicoplanin, vancomycin J01XA, A07AA09
Antipseudomonal penicillins with beta-lactamase inhibitor e.g., piperacillin + tazobactam J01CR03, J01CR05
Carbapenems e.g., meropenem, imipenem + cilastatin J01DH
Penems e.g., faropenem J01DI03
Reserve group
Medicine ATC code
Aztreonam J01DF01
Fourth-generation cephalosporins e.g., cefepime J01DE
Fifth-generation cephalosporins e.g., ceftaroline J01DI02, J01DI01, J01DI54
Fosfomycin IV J01XX01 (Only parenteral)
Oxazolidinone e.g., linezolid J01XX08, J01XX11
Polymyxins e.g., polymyxin B, colistin J01XB, A07AA10, A07AA05
Tigecycline J01AA12
Daptomycin J01XX09
∗Watch group antibiotics included in the EML/EMLc only for specific, limited indications; #ATC codes shown for medicines in the core access list – i.e., no overlap with
Watch group antibiotics.
Medicines not specifically identified in the groups described form an “ungrouped” medicines category.
analyses from the main class (level 1) to individual medicines
(level 5). National AMC focal points enter data on the numbers
of packages of each product imported or sold in their country,
relevant product information, population data, and assigned
DDD (World Health Organization Regional Office for Europe,
2017a; Table A1).
The core medicines monitored are the antibacterials for
systemic use (ATC group J01); antibiotics for alimentary tract
and metabolism (A07AA); and nitroimidazole derivatives
against amoebiasis and other protozoal diseases (P01AB).
There is optional data collection for antimycotics (J02),
antifungals (D01BA), and antivirals for systemic use
(J05), drugs for treatment of tuberculosis (J04A) and
antimalarials (P01B). Only data for the core medicines are
presented here.
Data Sources
Import data from customs records and declaration forms
is the most commonly reported source of information
supplemented with sales records from market authorization
holders, local manufacturing estimates, wholesaler records, and
in some cases, commercial data sources (see Supplementary
Table 1). Data represent total consumption estimates with
the exception of Kazakhstan where a commercial data
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BOX 3 | 2019 changes to DDDs for commonly prescribed J01 antibacterials.
ATC code Medicine Current DDD New DDD
J01CA04 Amoxicillin 1 g O 1.5g O
J01CA04 Amoxicillin 1 g P 3g P
J01CR02 Amoxicillin and beta- 1 g O 1.5g O
lactamase inhibitor
J01CA01 Ampicillin 2 g P 6g P
J01DE01 Cefepime 2 g P 4g P
J01DH02 Meropenem 2 g P 3g P
J01MA02 Ciprofloxacin 0.5 g P 0.8g P
J01XB01 Colistin 3 MU P 9 MU P
Source:https://www.whocc.no/atc/lists_of_new_atc_ddds_and_altera/alterations_
in_atc_ddd/. ATC, Anatomical Therapeutic Chemical; DDD, Defined Daily Dose;
g, gram; O, oral; P, parenteral; MU, million unit. Other changes to DDDs that
will apply in 2019: New DDDs are assigned for kanamycin oral (A07AA08);
colistin oral (A07AA10); cefroxadine (J01DB11); cefteram (J01DD18); ceftriaxone
and beta-lactamase inhibitor (J01DD63); tebipenem pivoxil (J01DH06); faropenem
(J01DI03); midecamycin (J01FA03); lomefloxacin (J01MA07); gemifloxacin
(J01MA15): garenoxacin (J01MA19); tosufloxacin (J01MA22); and delafloxacin
(J01MA23).
source provides coverage of around 80–85% of hospital
and community sales.
Data Validation
A template macro detects missing compulsory data and incorrect
data units. WHO Europe also reviews entries to identify data
inconsistencies, improbable estimates, errors in estimates for
combination products when converted to standardized units, and
a final data set for analysis is agreed.
Data Analysis and Metrics Reported
Total numbers of DDDs for each product are aggregated
to give the total number of DDDs at the desired ATC
code level and adjusted for population to calculate
DID. World Bank population estimates were applied
apart from Turkey, where estimates were adjusted to
take account of the large refugee and displaced persons
populations. Results are compared to publicly available
2015 ESAC-Net data that are derived using similar methods
(European Centre for Disease Control [ECDC], 2017).
Measures of relative consumption, expressed as a percentage
of total consumption of groups of antimicrobials, were
derived for pharmacological subgroups of J01, cephalosporins
and quinolones as a proportion of total J01 consumption,
cephalosporins by generation of agent, and for WHO Watch and
Reserve groups of antibiotics. These relative use measures
demonstrate the extent of consumption of second-line
and last resort antibiotics. Means, medians, and ranges of
estimates are presented to illustrate the variability of the 16
national datasets.
Changes in total and relative consumption between 2011 and
2015 are reported. The impact of changes to assigned DDDs in
2019 is explored for total consumption and relative consumption
estimates by applying DDDs for 2019 to numbers of packages
consumed in 2015. Change was calculated as the percentage
increase or decrease in total DDDs from the 2015 estimate using
2016 DDD values.
Role of the Funding Source
The funder (Netherlands Ministry of Health, Welfare and Sport)
had no role in study design, data collection, data analysis, data
interpretation, or writing the report.
RESULTS
Total antibiotic consumption (ATC group J01) in 2015 ranged
from 41.5 DID in Turkey to 8.0 DID in Azerbaijan (Figure 1).
Mean and median consumption were 21.2 and 19.0 DID,
respectively. The relative use of parenteral formulations varied
from 4% in Turkey and Bosnia and Herzegovina to 52%
in Uzbekistan (see Supplementary Figure 1). Beta-lactam
penicillins (ATC group J01C) were the most commonly used
antibiotics in almost all AMC Network countries, ranging from
56.6% of total J01 consumption in Kyrgyzstan to 16.2% in
Georgia. In Georgia, highest relative consumption was reported
for medicines in the sulfonamides and trimethoprim group (J01E,
26.4% of total consumption).
ESAC-Net estimates from 25 countries reporting both
community and hospital sector data in 2015 show similar
variability with a range from 38.3 DID in Greece to 11.7 DID
in Netherlands, with mean and median consumption of 22.6
and 22.2 DID, respectively [European Centre for Disease Control
(ECDC), 2017].
Figure 2 shows the consumption of cephalosporins and
quinolones as a proportion of total consumption of J01
antibacterials. Highest relative consumption of cephalosporins
was reported in Turkey (28.8%,) and lowest in Azerbaijan
(9.2%). Highest relative quinolone consumption was in
Georgia (24.6%). Together these two groups combined
represented 44% of total J01 consumption in Georgia to
20% of consumption in Kyrgyzstan.
There were high levels of consumption of first- and second-
generation cephalosporins in Bosnia and Herzegovina
(82% of total cephalosporin consumption) and Serbia
(75%). Consumption of third-generation agents that are
mostly second-line treatment options, and included in
the WHO Watch list, dominated in almost half of the
participating countries and represented up to 90% of total
cephalosporin consumption in Tajikistan and Georgia (Figure 3).
Reported consumption of fourth-generation agents (Reserve
category) was low.
WHO Watch and Reserve Category
Medicines
There were no or very low levels of consumption of Reserve
group antibiotics across the studied countries (0.01–0.83% of
total consumption; see Supplementary Table 2). Watch group
antibiotics comprised 49.5% of total J01 consumption in Georgia
to 17.3% of consumption in Kyrgyzstan (Figure 4). The mean and
median relative consumption of Watch group antibiotics were
30.9 and 30.5%, respectively.
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FIGURE 1 | Total consumption of J01 antibacterials by pharmacological subgroup in 15 countries and Kosovo, 2015. DDD, Defined Daily Dose; ∗Kosovo [in
accordance with United Nations Security Council resolution 1244 (1999)]; #Kazakhstan: commercial data source provides coverage of around 80–85% of hospital
and community sales.
FIGURE 2 | Consumption of cephalosporins and quinolones as a proportion of the total consumption of J01 antibacterials, 2015. ∗Kosovo [in accordance with
United Nations Security Council resolution 1244 (1999)].
Changes Over Time
There were decreases in total consumption estimates between
2011 and 2015 in nine countries, increases in five and in one
remaining reasonably stable over time (Table 1). Mean J01
consumption decreased from 23.6 to 21.2 DID between 2011 and
2015, and median consumption from 22.0 to 19.0 DID.
Within these changes in total DIDs, there were some
substantial changes in the reported consumption of parenteral
formulations: decreasing relative consumption in Azerbaijan
(47–22%) and Kyrgyzstan (72–42%) and increasing in Georgia
(16–36%) and Uzbekistan (42–52%).
Between 2011 and 2015, there were substantial increases
in relative consumption of the cephalosporin and quinolones
combined in Albania (22–37%), Azerbaijan (8–20%), Georgia
(19–44%), and Kyrgyzstan (9–20%). Conversely, there were
reductions in the consumption of these groups combined in
Turkey (42–37%) and Uzbekistan (33–23%).
Changes to DDDs in 2019
Applying the DDD changes to be implemented in 2019 to
consumption data for 2015 reduced total consumption estimates
from a range of 41.5–8.0 DID using 2016 DDD values to 35.5–
7.3 DID using 2019 DDD values (Table 2). The percentage
reductions in total DIDs ranged from 18.4 (Uzbekistan) to 4.3%
(Kazakhstan), with mean and median DID reductions of 12.0
and 13.0%, respectively, mostly due to reduced total DDDs for
penicillins. However, there was limited impact on rankings from
highest to lowest total consumption in DIDs (Table 2).
While absolute consumption estimates for cephalosporins and
quinolones changed very little, relative consumption of the two
groups combined increased slightly from 1.3% in Kazakhstan to
6.1% in Tajikistan (data not shown). Changes to DDD values
increased the estimate of relative consumption of Watch group
antibiotics – 17–49% of total consumption using 2016 DDD
values and 21–52% using 2019 DDD values (data not shown).
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FIGURE 3 | Relative consumption of cephalosporins by generation of agents, 2015. ∗Kosovo [in accordance with United Nations Security Council resolution 1244
(1999)].
FIGURE 4 | Consumption of “Watch” group of antibiotics classes as a proportion of total consumption of antibacterials. Watch group: Quinolones (J01MA and
J01MB); 3rd generation cephalosporins (J01DD); macrolides (J01FA); glycopeptides (J01XA and A07AA09); antipseudomonal penicillins with beta-lactamase inhibitor
(J01CR03 and J01CR05); carbapenems (J01DH); and faropenem (J01DI03). ∗Kosovo [in accordance with United Nations Security Council resolution 1244 (1999)].
DISCUSSION
Our main findings are that total antibiotic consumption in 2015
ranged from 8.0 DID for Azerbaijan to 41.5 DID for Turkey
(mean 21.2 DID). These estimates were mostly lower than those
reported in 2011 (range 6.4 DID Uzbekistan to Turkey 42.3 DID,
mean 23.6 DID). There were increases in relative consumption
of parenteral formulations, cephalosporins (particularly third-
generation agents), and quinolones that are included in the
WHO Watch list of antibiotics in several countries. Changes to
DDDs to be implemented in 2019 impacted on both total and
relative consumption estimates, driven mostly by DDD changes
for several commonly used beta-lactam penicillins. The impact of
the DDD changes on ranking of countries by total consumption
estimates was modest. Where the relative consumption of beta-
lactams was similar, there were similar percentage reductions in
total DIDs.
These observations are important given the paucity of
published data on antibiotic consumption from AMC network
countries and areas. An IQVIA MIDAS-based study used
national sample surveys of 2015 antibiotic sales extrapolated to
national sales volumes for 76 countries and reported quantitative
estimates of consumption for only two AMC Network members –
Turkey and Russian Federation (Klein et al., 2018). We report
total consumption of 41.5 DID for Turkey compared to Klein’s
estimate of around 47 DID. There are likely several reasons for
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TABLE 1 | Total antibiotic consumption 2011, 2015 in DDD/1000 inhabitants per
day.
J01 antibiotic consumption
DDD/1000 inhabitants per day
2011 2015
Albania 25.1 18.2
Armenia 15.9 10.7
Azerbaijan 17.1 8.0
Bosnia and Herzegovina 18.4 19.0
Belarus 17.9 19.0
Georgia 22.0 25.5
Kazakhstan# − 18.2
Kyrgyzstan 24.0 20.5
Republic of Moldova 21.3 13.8
Montenegro 38.3 33.9
Russian Federation 15.3 15.5
Serbia 26.4 36.5
Tajikistan 36.6 25.7
Turkey 42.3 41.5
Uzbekistan 6.4 10.5
Kosovo∗ 26.4 23.1
#commercial data source provides coverage of around 80–85% of hospital and
community sales; ∗ in accordance with United Nations Security Council resolution
1244 (1999).
these differences including the extrapolation and interpolation
algorithms applied to IQVIA data to generate national estimates
of consumption and the assignment of DDDs for all products
without a formal WHO DDD value. Medicines without an
assigned DDD are excluded from our analyses. Klein et al. (2018)
demonstrated good correlation of their estimates with ESAC-
Net data; however, it may reflect that IQVIA data collection in
EU countries is more comprehensive than in other parts of the
world, reducing the impact of the extrapolations applied. The
difference in absolute estimates of consumption in Turkey raises
questions about using such data for “setting and enforcing per
capita consumption targets” at the national level (Klein et al.,
2018). AMC Network data for Russian Federation are based
on IQVIA data, perhaps explaining the much closer estimates
of 15.5 and 16 DIDs from the two sources. Further work is
needed to compare consumption estimates from different data
sources – import records, wholesaler data, health insurance
records, and other commercial information sources – as the need
is for reliable, actionable data on antibiotic consumption that
can be used to monitor the impact of interventions to change
prescribing practices. We are aware for instance that there can be
considerable variation with import data from month to month.
Our estimates have some limitations, relying on a complete
register of antimicrobial products, full and accurate reporting of
data, distinguishing between medicines for local consumption
and export, and the impact of import cycles. In the absence
of universal health coverage or e-prescribing, widespread
availability of antibiotics without prescription, few mechanisms
to engage private wholesalers and limited ability to disaggregate
data to hospital and community sectors, import records
remain the most feasible data source in most AMC Network
countries and areas. However, the broad comparability of
TABLE 2 | Impact of 2019 changes in DDDs on estimates of total antibiotic consumption and ranking of countries.
2016 DDD values 2019 DDD values
Change
Rank∗ DID# Rank∗ DID# % decrease in rank
Turkey 1 41.5 1 35.5 14.5 –
Serbia 2 36.5 2 31.0 15.1 –
Montenegro 3 33.9 3 29.0 14.4 –
Tajikistan 4 25.7 5 21.6 16.0 −1
Georgia 5 25.5 4 24.2 5.1 +1
Kosovo§ 6 23.1 6 20.0 13.6 –
Kyrgyzstan 7 20.5 8 16.7 18.4 −1
Belarus 8 19.0 9 17.0 10.3 −1
Bosnia and Herzegovina 9 19.0 11 16.2 14.7 −2
Kazakhstan 10 18.2 7 17.4 4.3 +3
Albania 11 18.2 10 16.3 10.5 +1
Russian federation 12 15.5 12 14.1 9.2
Republic of Moldova 13 13.8 13 12.9 7.0 –
Armenia 14 10.7 14 9.4 12.5 –
Uzbekistan 15 10.5 15 8.6 18.4 –
Azerbaijan 16 8.0 16 7.3 7.9 –
Mean 21.0 18.4
Median 19.0 16.5
Range 8.0–41.5 7.3–35.5
∗highest to lowest; #DID DDD/1000 inhabitants per day; §in accordance with United Nations Security Council resolution 1244 (1999).
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total consumption estimates for AMC Network and ESAC-Net
countries suggest that estimates reported here are plausible and
can provide a platform for national level discussions and actions.
Reported decreases in total DIDs in this study are credible,
reflecting sustained efforts at the national level to improve
antibiotics use. Turkish health authorities have implemented
an electronic prescription system to track prescription data
and provide feedback to physicians and adopted a Rational
Drug Use National Action Plan 2014–2017 that prioritizes
the appropriate use of antibiotics (World Health Organization
Regional Office for Europe, 2017b). 2011 Turkey estimates
(42.3 DID) relied on commercial IMS data and reflected
community consumption; the comparable community estimate
in 2015 was 40.0 DID, derived from the comprehensive
pharmaceutical “track and trace” system that follows medicines
from production to consumption (Government of Turkey, 2018).
2015 data are also unlikely to reflect the full impact of the
sustained educational and regulatory interventions undertaken
since 2014.
The reduction in total antibiotic consumption from 15.9 to
10.7 DID between 2011 and 2015 in Armenia is likely related
to targeted awareness activities conducted by the multisectoral
team of the Ministry of Health. Multiple ongoing reforms
and activities in Azerbaijan targeting physicians, pharmacists
and patients are suggested to have contributed to reducing
total antibiotic consumption from 17.1 to 8.0 DID in the
same time period (Abilova et al., 2018). However, changes
in pricing policies have seen a shift from penicillins toward
consumption of tetracyclines, and while overall consumption of
cephalosporins was low, more than 80% was third-generation
agents. Pricing policies aimed at improving affordability and
access has affected market dynamics, with some manufacturers
leaving the market, influencing medicine choices (Abilova
et al., 2018). Pricing policies could be used to drive more
appropriate use, for example, lower prices for first- and
second-generation cephalosporins than third-generation agents
(Abilova et al., 2018).
More modest increases in total consumption in Georgia
(22.0 DID in 2011 to 25.5 DID in 2015) may reflect, in
part, issues in data collection, as exported products are not
fully accounted for. Nonetheless, there appear to be some
substantial shifts in consumption patterns, with reductions in
relative consumption of beta-lactams (67.7–16.2%), increases
in cephalosporins (8.8–19.2%) with more than 90% third-
generation agents, and increases in quinolone consumption
(10.5–24.6% of total J01 consumption). These observations
highlight the importance of metrics other than total volumes
of use. The choice of antimicrobial is as important as the
volume of use given increasing concerns with AMR, and
may be a more amenable target for changes in prescribing
practices and optimizing antibiotic use when supported by
evidence-based guidelines (World Health Organization, 2017a;
Klein et al., 2018). Serbia reported increased consumption
from 26.4 to 36.5 DID between 2011 and 2015. The reasons
for this require local level investigation. However, limited
resources have compromised the implementation of physician
education programs, promotion of rational use of antibiotics
and hospital-based antimicrobial stewardship programs
(Kalaba et al., 2018).
The DRIVE-AB project distinguishes between prescribing
quality indicators and quantitative metrics, proposing 51
inpatient and 32 outpatient quality indicators covering aspects
including stewardship, diagnostics, dosing, duration, safety and
monitoring of antibiotics, as well as 12 inpatient and 6 outpatient
quantity metrics (DRIVE-AB, 2014). A quality indicator reflects
the degree in which the antibiotic is correct or appropriate,
where the outcome has a value on its own. A quantity metric
reflects the volume or costs of antibiotic use and the outcome
only gains value in its comparison. By these definitions, most
of the metrics presented here are quantitative metrics, although
quantitative measures focusing on preferred agents might be
considered pointing toward improved prescribing practices and
some measure of quality. This is the first step though to improve
future antibiotic use in the absence of patient level data, especially
given the high rate of self-purchasing of antibiotics without a
prescription in a number of network countries.
Metrics such as packages of medicines per 1000 inhabitants
per day have been proposed as an alternative to DIDs in
the outpatient setting, partly in response to differences in
prescribed daily doses in different countries (Bruyndonckx et al.,
2014; Coenen et al., 2014; Watier et al., 2017). However,
consumption estimates are affected by choice of measurement
unit underpinning the importance of the use of the same data
sources and metrics over time for assessment of temporal trends
and benchmarking (Watier et al., 2017). Patient-linked volume
of use measures are being used as national prescribing targets,
with Sweden adopting a long-term goal of 250 prescriptions
per 1000 inhabitants/year for all age groups, and the 2016 UK
government proposing to halve inappropriate prescribing by
2020 (Government of Sweden, 2016; UK Department of Health
Media Centre, 2016). However, prescription data are not available
in all settings especially among AMC member countries and
areas. Assessment of appropriate use (quality indicators) requires
patient-level information linking clinical condition, patient
characteristics and prescribing choices. Clinicians will more likely
respond to these data than higher level aggregate measures. As
health information systems develop, it will become possible to
move beyond quantitative metrics toward quality indicators. In
the interim, focused studies such as point prevalence studies,
prescription analyses, and community surveys supplemented
with qualitative studies are being undertaken in AMC Network
countries and areas to help fill the information gaps and provide
evidence of practices that should be reviewed (Smiljanic et al.,
2016). There are also ongoing activities to improve pharmacist
and patient knowledge to reduce inappropriate dispensing
of antibiotics especially for upper respiratory tract infections
(Markovic-Pekovic et al., 2017; Hoxha et al., 2018).
Policymakers and consumers require simple metrics that
are easily interpretable, identify the magnitude of problems
with antibiotic consumption and suggest the need for policy
actions such as regulations, the enforcement of prescription-
only status and investments in education and training. In
the absence of prescription data, total consumption in DID
could be used for this purpose although is difficult to interpret
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in isolation requiring trend data at the national or cross-
national level to provide some context (Van Boeckel et al., 2014;
Versporten et al., 2014; World Health Organization Regional
Office for Europe, 2017a). DDD changes in 2019 will likely
compound the problems of interpretation of consumption
estimates, with total DIDs decreasing on average by around 12%
with the new DDDs applied, independent of any intervention
by government, agencies or professional groups. Communication
strategies will be required so stakeholders are aware of the
impact of the DDD changes along with re-setting of trend
lines and targets for changes in antibiotic consumption at the
national level.
The WHO Watch and Reserve group classifications offer
promise as metrics that indicate actions required and lend
themselves to prescribing targets with lower absolute and
relative levels of consumption of these groups of antibiotics
desirable. The Access, Watch, and Reserve classifications are
already being applied – to IQVIA sales data units for single
molecule and combination antibiotic products in India, and in
the Access to Medicines Foundation analysis of proportions of
pharmaceutical companies’ marketed antibiotics that are listed
in the WHO EML antibiotic groups (McGettigan et al., 2017;
Access to Medicines Foundation, 2018). More relevant for
national stewardship efforts is an analysis of relative consumption
of antibiotics by the WHO groups. However, a standardized
method of calculation (ATC codes included and denominator
definitions) is needed to ensure the validity of comparisons
between settings (community, hospital, and total consumption)
and for monitoring changes over time. The estimates presented
here are based on total consumption – the relative use of Watch
and Reserve groups would be substantially higher in a hospital-
based analysis. The lists of Watch and Reserve medicines will
be modified as evidence emerges, and more clinical conditions
are reviewed.
While the quantitative metrics presented have limited
application in assessing the appropriateness of prescribing,
they do illustrate differing patterns of antibiotic consumption
between countries and within countries over time and point
to potential problems in antibiotic use. A full exploration of
reasons for the changes in consumption patterns reported
in each of the 16 AMC Network countries and areas is
beyond the scope of this study. However, the impact of locally
produced antibiotics on treatment choices, pharmaceutical
industry promotion, perverse incentives to prescribe and
dispense antibiotics, availability and use of up-to-date guidelines
all need to be considered in developing interventions to
improve antibiotic use. Quantitative measures can be effective.
Turkish health authorities responded to high levels of antibiotic
consumption with substantial commitments of resources and
integrated activities to improve antibiotic use (World Health
Organization Regional Office for Europe, 2017b). Relative
use measures targeting less appropriate treatment choices
(third- and fourth-generation cephalosporins, quinolones,
Watch and Reserve antibiotics) may be more effective
with clinicians and provide targets for action supported by
evidence-based guidelines and treatment protocols. Other
measures such as the removal of incentives to prescribe and
dispense antibiotics, enforcement of prescription-only status,
better diagnostics, favoring narrow-spectrum over broad-
spectrum antibiotics and raising awareness and education
of the public regarding the importance of preserving
the value of existing antibiotics are also required. These
are considerations for the future among AMC Network
countries and areas, and we will be reporting further on this
in the future.
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APPENDIX
TABLE A1 | List of AMC focal points and contributors to the 2015 data collection.
Albania Iris Hoxha Department of Pharmacy, University of Medicine, Tirana
Armenia Lilit Ghazaryan∗ Scientific Centre of Drug and Medical Technology Expertise of Ministry of Health
Azerbaijan Vafa Abilova∗ Department of Import Medicines and Medical Devices, Analytical Expertise Center, Ministry of Health
Nazifa Mursalova∗ Sector of Sanitary Epidemiological Surveillance Ministry of Health
Bosnia and Herzegovina Ana Cvijanovic Sector for Providing Information on Drugs and Medical Products in Agency for Medicinal Products
and Medical Devices of Bosnia and Herzegovina
Tijana Spasojevic∗ Sector for Providing Information on Drugs and Medical Products in Agency for Medicinal Products
and Medical Devices of Bosnia and Herzegovina
Belarus Halina Pyshnik∗ Department of Pharmaceutical Inspection and Organization of Medicines Supply, Ministry of Health
Georgia Marina Darakhvelidze∗ Health Care Department, Ministry of IDPs, Labour, Health and Social Affairs of Georgia
Marine Baidauri Regulations Division of Health Care Department, Ministry of IDPs, Labour, Health and Social Affairs
of Georgia
David Tsereteli National Center for Disease Control and Public Health
Kazakhstan Larissa Makalkina Department of Cardiology and Internal Medicine with a course of clinical pharmacology and
Pharmacy, Astana Medical University
Zhannat Asina Kazan Federal University, Alphateam LLP
Kyrgyzstan Ismailova Baktygul
Abdyldaevna∗
Public Health Unit, Ministry of Health
Aigul Dzhakubekova∗ Unit on Specialized Expertise of Medicines of Department of Drug Provision and Medical Devices,
Ministry of Health
Republic of Moldova Nicolae Furtuna∗ National Public Health Centre
Angela Carp P.I. Coordination, Implementation and Monitoring Unit of the Health System Projects
Montenegro Lidija Cizmovic∗ Department for Establishing Maximum Prices and Monitoring Consumption of Medicines, Agency
for Medicines and Medical Devices
Russian Federation Svetlana Rachina Internal Medicine Department with Cardiology and Functional Diagnostics Course named after
academician V.S. Moiseev, Russian Friendship University, Moscow, Russian Federation,
Interregional Association for Clinical Microbiology & Antimicrobial Chemotherapy, Russian
Federation
Serbia Vesela Radonjic∗ National Centre for Information on Medicines and Medical Device, Medicines and Medical Devices
Agency of Serbia
Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Serbia
Tajikistan Nargis Maqsudova Health Systems, WHO Country Office in Tajikistan
Salomudin Yusufi Vice-Rector for Science, Avicenna Tajik State Medical University
Turkey Melda Kecik
Mesil Aksoy∗
Department of Rational Use of Medicines. Turkish Medicines and Medical Devices Agency, Ministry
of Health of Turkey
Ali Alkan Vice Presidency of Medicines and Pharmacy Turkish Medicines and Medical Devices Agency,
Ministry of Health of Turkey
Hakki Gursoz Turkish Medicines and Medical Devices Agency, Ministry of Health of Turkey,
Bahar Melik
Fatma I˙sli∗
Emre Umut Gurpinar
Serap Tekbacak
Omer Hakan Simsek
Uzbekistan Muhabbat Ibragimova∗ The State Center for Expertise and Standardization of Medicines, Medical Devices and Medical
Equipment of the Agency for the Development of the Pharmaceutical Industry under the Ministry of
Health of the Republic of Uzbekistan
Kosovo# Arianit Jakupi∗ A2 - Pharmaceutical Consulting and UBT - Higher Education Institution
∗Nominated AMC focal points; # in accordance with Security Council resolution 1244 (1999).
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